DRTG(SH:600329) Zheng Quan Zhi Xing·2025-05-29 08:19Group 1 - The company intends to transfer its 12% stake in Tianjin Sike Pharmaceutical Co., Ltd. to Haleon (China) Co., Ltd. and Haleon CH SARL, aiming to enhance cash flow and focus on core business [1][20] - The transaction price for the 4.6% stake transfer to Haleon (China) is set at approximately 1,001,137,777.78 RMB, with the total transaction value reflecting a 35% premium over the assessed asset value [1][7][20] - The transaction is not classified as a related party transaction and does not constitute a major asset restructuring as per regulations [2][20] Group 2 - Haleon (China) Co., Ltd. is a wholly foreign-owned enterprise established in 2015, with a registered capital of 195,161,000 RMB and a diverse range of business activities including medical device sales and health consulting [2][3] - Haleon CH SARL, established in 1991, operates as an investment holding company with significant assets and revenue, indicating a strong financial position [4][5] - The financial data of Tianjin Sike shows total assets of 308,784.39 million RMB and net profit of 98,165.56 million RMB for the audited period, reflecting its operational viability [5][20] Group 3 - The transaction is expected to generate approximately 1.623 billion RMB in revenue for the company, with an estimated net profit increase of around 13 billion RMB after tax implications [20] - The company plans to utilize the funds from this transaction for business expansion, including strategic acquisitions, R&D projects, and working capital [20] - The transaction aligns with the company's strategy to enhance shareholder value and does not adversely affect its operational independence [20]